HK1163813A1 - Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath adm / - Google Patents

Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath adm /

Info

Publication number
HK1163813A1
HK1163813A1 HK12104225.5A HK12104225A HK1163813A1 HK 1163813 A1 HK1163813 A1 HK 1163813A1 HK 12104225 A HK12104225 A HK 12104225A HK 1163813 A1 HK1163813 A1 HK 1163813A1
Authority
HK
Hong Kong
Prior art keywords
adm
shortness
breath
agent
manufacturing
Prior art date
Application number
HK12104225.5A
Other languages
English (en)
Chinese (zh)
Inventor
Andreas Bergmann
Oliver Hartmann
Original Assignee
有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 有限公司 filed Critical 有限公司
Publication of HK1163813A1 publication Critical patent/HK1163813A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12104225.5A 2008-11-11 2012-04-30 Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath adm / HK1163813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168816 2008-11-11
US11364908P 2008-11-12 2008-11-12
PCT/EP2009/008056 WO2010054810A1 (en) 2008-11-11 2009-11-06 Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp

Publications (1)

Publication Number Publication Date
HK1163813A1 true HK1163813A1 (en) 2012-09-14

Family

ID=41666661

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12104225.5A HK1163813A1 (en) 2008-11-11 2012-04-30 Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath adm /

Country Status (7)

Country Link
US (1) US20100159474A1 (xx)
EP (1) EP2347266B9 (xx)
JP (1) JP5584695B2 (xx)
CN (1) CN102317790B (xx)
ES (1) ES2431358T3 (xx)
HK (1) HK1163813A1 (xx)
WO (1) WO2010054810A1 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533972B (zh) 2002-05-09 2014-07-02 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的1l1rl-1
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP4357783A2 (en) 2006-04-04 2024-04-24 Novilux, LLC Highly sensitive system and methods for analysis of troponin
DK2848938T3 (da) 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
EP2660599B1 (en) 2008-04-18 2014-09-10 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
CN101957367B (zh) * 2010-07-30 2014-10-22 北京热景生物技术有限公司 一种心衰诊断的上转发光快速定量试剂盒
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
US8748110B2 (en) 2011-07-18 2014-06-10 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
WO2013022760A1 (en) * 2011-08-05 2013-02-14 Alere San Diego, Inc. Methods and compositions for monitoring heart failure
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
WO2014031764A1 (en) * 2012-08-21 2014-02-27 Critical Care Diagnostics, Inc. Multimarker risk stratification
CN105960593B (zh) * 2013-11-04 2018-05-15 密歇根大学董事会 用于慢性肾病进展预测的生物标记物和方法
WO2015106081A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
EP3371600A1 (en) * 2015-11-06 2018-09-12 MyCartis N.V. Use of cd146 as a marker of the vascular wall tension
JP6944449B2 (ja) * 2015-11-27 2021-10-06 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ
CN109716136B (zh) * 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血
CA3033102A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
CN109564225B (zh) * 2016-08-09 2022-05-13 B.R.A.H.M.S 有限公司 作为指示不良事件的标志物的组蛋白和/或proADM
US11041867B2 (en) 2017-02-02 2021-06-22 B.R.A.H.M.S Gmbh ProADM and/or histones as markers indicating an adverse event
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7361473B2 (en) * 2001-05-04 2008-04-22 Biosite, Incorporated Diagnostic markers of acute coronary syndrome and methods of use thereof
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
ATE392623T1 (de) * 2004-07-22 2008-05-15 Brahms Ag Verfahren für die diagnose von schwerkranken patienten
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
DE102006052916A1 (de) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM

Also Published As

Publication number Publication date
EP2347266B9 (en) 2014-02-12
EP2347266A1 (en) 2011-07-27
US20100159474A1 (en) 2010-06-24
WO2010054810A1 (en) 2010-05-20
JP2012508386A (ja) 2012-04-05
ES2431358T3 (es) 2013-11-26
CN102317790A (zh) 2012-01-11
JP5584695B2 (ja) 2014-09-03
CN102317790B (zh) 2014-12-10
EP2347266B1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
HK1163813A1 (en) Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath adm /
IL290501A (en) Systems and methods for extracorporeal lung preservation
EP2240187A4 (en) INGREDIENTABLE ABSORBENT AGENTS AND METHODS OF MAKING AND USING SAME
GB2456813B (en) Diagnostic context construction and comparison
EP2327750A4 (en) LIABILITY AND LIABILITY THEREWITH
ZA201009224B (en) Il-1a abs and methods of use
EP2252333A4 (en) WOUND AND GAS TISSUE TREATMENTS
PL2132987T3 (pl) Kompozycja środka nicieniobójczego oraz sposób jej zastosowania
EP2287589A4 (en) GROUNDING MEMBRANE, METAL MOLD AND METHOD FOR ASSESSING AN ACTIVE SUBSTANCE FOR EXTERNAL APPLICATION TO THE SKIN
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
PT2130435E (pt) Agente para melhorar a resistência de plantas a bases e método para melhorar a resistência de plantas a bases
GB0716885D0 (en) Diagnostic agent
EP2434536A4 (en) MEANS AND METHOD FOR FINE PROCESSING
EP2282648A4 (en) PREBIOTIC COMPOSITIONS AND MANUFACTURING AND USE METHOD THEREFOR
EP2286479A4 (en) BATTERY PARTS AND SAME MANUFACTURING AND USE METHOD
GB201108964D0 (en) Medicament and method of diagnosis
ZA200808950B (en) Garment for use with an absorbent structure and its methods of manufacture
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
EP2300495A4 (en) SOLUTIONS FOR TISSUE MANIPULATION AND APPLICATION METHODS
HK1168793A1 (en) Glucose metabolism-improving agent and glucose metabolism-improving composition
EP2323707A4 (en) MANUFACTURE AND USE OF COMPOSITE FRAMES
EP2350001A4 (en) NEW BENZYLIDENE INDOLINOES AND THEIR MEDICAL AND DIAGNOSTIC USES
ZA201102857B (en) Anti-infective formulation and methods of use
EP2345660A4 (en) ANTI-XDR-TB-MEDIUM, ANTI-MDR-TB-MEDIUM AND COMBINED ANTIBODY CLOUD
GB0705395D0 (en) Breath deodoriser